ADMA BIOLOGICS, INC. Cost of Revenue
ADMA BIOLOGICS, INC. (ADMA) reported Cost of Revenue of $38.12 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Expense Statement
us-gaap:CostOfRevenue · last filed 2026-08-05
- ADMA BIOLOGICS, INC. cost of revenue for the quarter ending 2026-06-30 was $38.12M, a 30.39% decline year-over-year.
- ADMA BIOLOGICS, INC. cost of revenue for the quarter ending 2026-03-31 was $33.74M, a 37.17% decline year-over-year.
- ADMA BIOLOGICS, INC. cost of revenue for the quarter ending 2025-12-31 was $50.35M, a 7.14% decline year-over-year.
- ADMA BIOLOGICS, INC. cost of revenue for the quarter ending 2025-09-30 was $58.60M, a 2.63% decline year-over-year.
- ADMA BIOLOGICS, INC. cost of revenue for fiscal 2025 was $217.41M, a 5.08% increase from fiscal 2024.
- ADMA BIOLOGICS, INC. cost of revenue for fiscal 2024 was $206.90M, a 22.23% increase from fiscal 2023.
- ADMA BIOLOGICS, INC. cost of revenue for fiscal 2023 was $169.27M, a 42.47% increase from fiscal 2022.
- ADMA BIOLOGICS, INC. cost of revenue for fiscal 2022 was $118.81M, a 48.95% increase from fiscal 2021.
| Period end | Cost of Revenue 3 month | Cost of Revenue 3 month as first filed | Cost of Revenue 6 month | Cost of Revenue 6 month as first filed | Cost of Revenue 9 month | Cost of Revenue 9 month as first filed | Cost of Revenue 12 month | Cost of Revenue 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $38.12M 10-Q · filed 2026-08-05 | $71.86M 10-Q · filed 2026-08-05 | $122.21M derived: sum of 3 quarters · filed 2026-08-05 | $180.81M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2026-03-31 | $33.74M 10-Q · filed 2026-05-06 | $84.09M derived: sum of 2 quarters · filed 2026-05-06 | $142.69M derived: sum of 3 quarters · filed 2026-05-06 | $197.44M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2025-12-31 | $50.35M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $108.94M derived: sum of 2 quarters · filed 2026-02-25 | $163.70M derived: sum of 3 quarters · filed 2026-08-05 | $217.41M 10-K · filed 2026-02-25 | ||||
| 2025-09-30 | $58.60M 10-Q · filed 2025-11-05 | $113.36M derived: sum of 2 quarters · filed 2026-08-05 | $167.06M 10-Q · filed 2025-11-05 | $221.28M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2025-06-30 | $54.76M 10-Q · filed 2026-08-05 | $108.46M 10-Q · filed 2026-08-05 | $162.68M derived: sum of 3 quarters · filed 2026-08-05 | $222.86M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2025-03-31 | $53.70M 10-Q · filed 2026-05-06 | $107.92M derived: sum of 2 quarters · filed 2026-05-06 | $168.10M derived: sum of 3 quarters · filed 2026-05-06 | $217.84M derived: sum of 4 quarters · filed 2026-05-06 | ||||
| 2024-12-31 | $54.22M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $114.40M derived: sum of 2 quarters · filed 2026-02-25 | $164.13M derived: sum of 3 quarters · filed 2026-02-25 | $206.90M 10-K · filed 2026-02-25 | ||||
| 2024-09-30 | $60.18M 10-Q · filed 2025-11-05 | $109.92M derived: sum of 2 quarters · filed 2025-11-05 | $152.69M 10-Q · filed 2025-11-05 | $195.50M derived: sum of 4 quarters · filed 2026-02-25 | ||||
| 2024-06-30 | $49.74M 10-Q · filed 2025-08-06 | $92.50M 10-Q · filed 2025-08-06 | $135.32M derived: sum of 3 quarters · filed 2026-02-25 | $177.94M derived: sum of 4 quarters · filed 2026-02-25 | ||||
| 2024-03-31 | $42.77M 10-Q · filed 2025-05-07 | $85.58M derived: sum of 2 quarters · filed 2026-02-25 | $128.21M derived: sum of 3 quarters · filed 2026-02-25 | $171.64M derived: sum of 4 quarters · filed 2026-02-25 | ||||
| 2023-12-31 | $42.82M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $85.44M derived: sum of 2 quarters · filed 2026-02-25 | $128.87M derived: sum of 3 quarters · filed 2026-02-25 | $169.27M 10-K · filed 2026-02-25 | ||||
| 2023-09-30 | $42.62M 10-Q · filed 2024-11-07 | $42.62M 10-Q · filed 2023-11-08 | $86.06M derived: sum of 2 quarters · filed 2024-11-07 | $126.45M 10-Q · filed 2024-11-07 | $126.46M 10-Q · filed 2023-11-08 | $162.26M derived: sum of 4 quarters · filed 2025-03-18 | ||
| 2023-06-30 | $43.43M 10-Q · filed 2024-08-08 | $43.43M 10-Q · filed 2023-08-09 | $83.83M 10-Q · filed 2024-08-08 | $83.83M 10-Q · filed 2023-08-09 | $119.64M derived: sum of 3 quarters · filed 2025-03-18 | $151.07M derived: sum of 4 quarters · filed 2025-03-18 | ||
| 2023-03-31 | $40.40M 10-Q · filed 2024-05-09 | $40.40M 10-Q · filed 2023-05-10 | $76.21M derived: sum of 2 quarters · filed 2025-03-18 | $107.64M derived: sum of 3 quarters · filed 2025-03-18 | $133.77M derived: sum of 4 quarters · filed 2025-03-18 | |||
| 2022-12-31 | $35.80M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-18 | $67.24M derived: sum of 2 quarters · filed 2025-03-18 | $93.37M derived: sum of 3 quarters · filed 2025-03-18 | $118.81M 10-K · filed 2025-03-18 | $118.81M 10-K · filed 2023-03-23 | |||
| 2022-09-30 | $31.43M 10-Q · filed 2023-11-08 | $57.57M derived: sum of 2 quarters · filed 2023-11-08 | $83.01M 10-Q · filed 2023-11-08 | $105.88M derived: sum of 4 quarters · filed 2024-02-28 | ||||
| 2022-06-30 | $26.14M 10-Q · filed 2023-08-09 | $51.58M 10-Q · filed 2023-08-09 | $74.45M derived: sum of 3 quarters · filed 2024-02-28 | $94.74M derived: sum of 4 quarters · filed 2024-02-28 | ||||
| 2022-03-31 | $25.44M 10-Q · filed 2023-05-10 | $48.31M derived: sum of 2 quarters · filed 2024-02-28 | $68.61M derived: sum of 3 quarters · filed 2024-02-28 | $87.44M derived: sum of 4 quarters · filed 2024-02-28 | ||||
| 2021-12-31 | $22.87M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | $43.17M derived: sum of 2 quarters · filed 2024-02-28 | $62.00M derived: sum of 3 quarters · filed 2024-02-28 | $79.77M 10-K · filed 2024-02-28 | $79.77M 10-K · filed 2022-03-24 | |||
| 2021-09-30 | $20.30M 10-Q · filed 2022-11-09 | $39.13M derived: sum of 2 quarters · filed 2022-11-09 | $56.90M 10-Q · filed 2022-11-09 | $76.01M derived: sum of 4 quarters · filed 2022-11-09 | ||||
| 2021-06-30 | $18.83M 10-Q · filed 2022-08-10 | $36.60M 10-Q · filed 2022-08-10 | $55.71M derived: sum of 3 quarters · filed 2022-08-10 | $67.57M derived: sum of 4 quarters · filed 2022-08-10 | ||||
| 2021-03-31 | $17.77M 10-Q · filed 2022-05-11 | $36.88M derived: sum of 2 quarters · filed 2022-05-11 | $48.74M derived: sum of 3 quarters · filed 2022-05-11 | $62.23M derived: sum of 4 quarters · filed 2022-05-11 | ||||
| 2020-12-31 | $19.11M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-24 | $30.97M derived: sum of 2 quarters · filed 2022-03-24 | $44.46M derived: sum of 3 quarters · filed 2022-03-24 | $61.29M 10-K · filed 2022-03-24 | ||||
| 2020-09-30 | $11.86M 10-Q · filed 2020-11-05 | $25.35M derived: sum of 2 quarters · filed 2020-11-05 | $42.18M 10-Q · filed 2020-11-05 | $53.87M derived: sum of 4 quarters · filed 2021-05-12 | ||||
| 2020-06-30 | $13.50M 10-Q · filed 2020-08-05 | $30.32M 10-Q · filed 2020-08-05 | $42.02M derived: sum of 3 quarters · filed 2021-05-12 | $49.93M derived: sum of 4 quarters · filed 2021-05-12 | ||||
| 2020-03-31 | $16.83M 10-Q · filed 2021-05-12 | $28.52M derived: sum of 2 quarters · filed 2021-05-12 | $36.44M derived: sum of 3 quarters · filed 2021-05-12 | $46.93M derived: sum of 4 quarters · filed 2021-05-12 | ||||
| 2019-12-31 | $11.69M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-25 | $19.61M derived: sum of 2 quarters · filed 2021-03-25 | $30.10M derived: sum of 3 quarters · filed 2021-03-25 | $39.50M 10-K · filed 2021-03-25 | ||||
| 2019-09-30 | $7.92M 10-Q · filed 2020-11-05 | $18.41M derived: sum of 2 quarters · filed 2020-11-05 | $27.81M 10-Q · filed 2020-11-05 | $38.95M derived: sum of 4 quarters · filed 2020-11-05 | ||||
| 2019-06-30 | $10.49M 10-Q · filed 2020-08-05 | $19.90M 10-Q · filed 2020-08-05 | $31.04M derived: sum of 3 quarters · filed 2020-08-05 | $40.20M derived: sum of 4 quarters · filed 2020-08-05 | ||||
| 2019-03-31 | $9.41M 10-Q · filed 2020-05-06 | $20.55M derived: sum of 2 quarters · filed 2020-05-06 | $29.71M derived: sum of 3 quarters · filed 2020-05-06 | $39.36M derived: sum of 4 quarters · filed 2020-05-06 | ||||
| 2018-12-31 | $11.14M 10-K · filed 2019-03-13 | $20.31M derived: sum of 2 quarters · filed 2019-11-06 | $29.95M derived: sum of 3 quarters · filed 2019-11-06 | $42.19M 10-K · filed 2020-03-13 | ||||
| 2018-09-30 | $9.16M 10-Q · filed 2019-11-06 | $18.81M derived: sum of 2 quarters · filed 2019-11-06 | $31.05M 10-Q · filed 2019-11-06 | $42.98M derived: sum of 4 quarters · filed 2019-11-06 | ||||
| 2018-06-30 | $9.65M 10-Q · filed 2019-08-08 | $21.89M 10-Q · filed 2019-08-08 | $33.81M derived: sum of 3 quarters · filed 2019-08-08 | $45.10M derived: sum of 4 quarters · filed 2019-08-08 | ||||
| 2018-03-31 | $12.24M 10-Q · filed 2019-05-08 | $195.02K 10-Q · filed 2018-05-14 | $24.17M derived: sum of 2 quarters · filed 2019-05-08 | $35.46M derived: sum of 3 quarters · filed 2019-05-08 | $39.79M derived: sum of 4 quarters · filed 2019-05-08 | |||
| 2017-12-31 | $11.92M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-13 | $23.21M derived: sum of 2 quarters · filed 2019-03-13 | $27.55M derived: sum of 3 quarters · filed 2019-03-13 | $29.16M 10-K · filed 2019-03-13 | $2.78M 10-K · filed 2018-03-29 | |||
| 2017-09-30 | $11.29M 10-Q · filed 2018-11-09 | $1.41M 10-Q · filed 2017-11-03 | $15.63M derived: sum of 2 quarters · filed 2018-11-09 | $17.24M 10-Q · filed 2018-11-09 | $1.74M 10-Q · filed 2017-11-03 | $16.20M derived: sum of 4 quarters · filed 2018-11-09 | ||
| 2017-06-30 | $4.33M 10-Q · filed 2018-08-10 | $141.75K 10-Q · filed 2017-08-11 | $5.95M 10-Q · filed 2018-08-10 | $324.14K 10-Q · filed 2017-08-11 | $4.91M derived: sum of 3 quarters · filed 2018-08-10 | $5.23M derived: sum of 4 quarters · filed 2018-08-10 | ||
| 2017-03-31 | $182.39K 10-Q · filed 2018-05-14 | $573.88K derived: sum of 2 quarters · filed 2018-05-14 | $900.70K derived: sum of 3 quarters · filed 2018-05-14 | $1.28M derived: sum of 4 quarters · filed 2018-05-14 | ||||
| 2016-12-31 | $391.50K derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-29 | $718.32K derived: sum of 2 quarters · filed 2018-03-29 | $1.10M derived: sum of 3 quarters · filed 2018-03-29 | $1.61M 10-K · filed 2018-03-29 | ||||
| 2016-09-30 | $326.82K 10-Q · filed 2017-11-03 | $709.50K derived: sum of 2 quarters · filed 2017-11-03 | $1.22M 10-Q · filed 2017-11-03 | |||||
| 2016-06-30 | $382.69K 10-Q · filed 2017-08-11 | $888.25K 10-Q · filed 2017-08-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 |